PLASMATECH BIOPHARMACEUTICALS INC |
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 06-18 | Abeona Therapeutics Files for $300 Million Mixed Shelf, $75 Million At-The-Market Offering | MT |
| 05-30 | Stifel Starts Abeona Therapeutics With Buy Rating, $21 Price Target | MT |
Chart calendar Plasmatech Biopharmaceuticals Inc
8092909540a3b7e31af3d21.tgSXNf-BuWl4U14zk7UTQ8RWBEsFaowWyeNPJ0Utdjc.9FGhUorS7F0uNSpRyt4nAbcsRxJ3KflivtsdQX0VOHrkZsd_kNeBCg0EEw~ba937fabdbc7cfa2de1d21f4c81f486b
Upcoming events on Plasmatech Biopharmaceuticals Inc
Past events on Plasmatech Biopharmaceuticals Inc
| 2024-06-06 11:30 | Jefferies Global Healthcare Conference |
| 2024-05-15 08:30 | Q1 2024 Earnings Call |
| 2024-05-15 07:30 | Q1 2024 Earnings Release |
| 2024-04-24 09:00 | Annual General Meeting |
| 2024-04-23 08:30 | Prademagene Zamikeracel FDA Approval Call |
| 2024-03-18 08:30 | Q4 2023 Earnings Call |
| 2024-03-18 07:30 | Q4 2023 Earnings Release |
| 2023-11-13 08:30 | Q3 2023 Earnings Call |
| 2023-11-13 07:30 | Q3 2023 Earnings Release |
| 2023-09-27 09:30 | Jefferies Cell & Genetic Medicine Summit |
| 2023-09-26 14:10 | Cantor Global Healthcare Conference |
| 2023-09-13 10:00 | H.C. Wainwright Global Investment Conference |
| 2023-08-08 08:30 | Q2 2023 Earnings Call |
| 2023-08-08 07:30 | Q2 2023 Earnings Release |
| 2023-06-09 09:00 | Jefferies Global Healthcare Conference - Fireside Chat |
| 2023-05-24 08:30 | Business Update Call - Q1 2023 Earnings |
| 2023-05-19 15:00 | American Society of Gene Cell Therapy Meeting - Abstract Number: 1478 |
| 2023-05-18 15:00 | American Society of Gene Cell Therapy Meeting - Abstract Number: 1131 |
| 2023-05-17 15:00 | American Society of Gene Cell Therapy Meeting - Abstract Number: 715 |
| 2023-05-17 09:00 | Annual General Meeting |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 10,0 9,28 7.82% | 3,00 0,00 - | 1,41 2,32 -39.13% | 3,50 3,50 0% | 0,30 |
|
EBITDA | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
|
EBIT Million USD | Released Forecast Spread | -77,1 -79,9 3.55% | -81,4 -79,9 -1.91% | -89,8 -58,8 -52.71% | -50,9 -44,6 -14.2% | -47,1 -45,3 -4.11% | -60,5 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -76,3 -79,1 3.54% | -84,2 -83,2 -1.24% | -84,9 -68,3 -24.36% | -39,7 -55,3 28.22% | -54,2 -45,0 -20.33% | -73,6 |
|
Net income Million USD | Released Forecast Spread | -76,3 -78,9 3.35% | -84,2 -81,3 -3.65% | -84,9 -59,0 -44% | -43,5 -53,9 19.37% | -54,2 -47,3 -14.59% | -73,6 |
|
EPS USD | Released Forecast Spread | -37,8 -37,8 0.19% | -22,8 -20,6 -10.53% | -21,5 -13,9 -54.49% | -5,53 -3,92 -41.25% | -2,53 -2,23 -13.45% | -1,89 |
| Announcement Date | 16/03/20 | 24/03/21 | 31/03/22 | 29/03/23 | 18/03/24 | - |
Quarterly results
| Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,35 0,00 - | 1,00 0,00 - | 0,00 0,00 - | 0,07 1,00 -93.2% | 0,00 0,00 - | 3,50 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,13 - | 0,10 | 0,10 | 0,10 | 0,25 | 0,25 |
|
EBIT Million USD | Released Forecast Spread | -20,6 -16,0 -28.69% | -8,01 -14,5 44.77% | -9,38 -10,3 8.49% | -12,9 -8,95 -44.54% | -12,0 -10,8 -11.98% | -11,6 -12,5 6.67% | -11,3 -13,2 13.81% | -13,2 -11,5 -14.86% | -14,3 -13,8 -3.84% | -14,6 | -15,5 | -16,1 | -18,1 | -18,1 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -20,8 -16,0 -29.94% | -8,30 -14,5 42.79% | -9,48 -10,5 9.68% | -1,13 -12,9 91.27% | -9,11 -10,8 15.68% | -16,7 -12,7 -31.48% | -11,8 -13,2 10.11% | -16,6 -11,5 -44.69% | -31,6 -14,0 -125.56% | -14,4 | -15,5 | -16,6 | -19,1 | -19,1 |
|
Net income Million USD | Released Forecast Spread | -20,8 -12,3 -69.72% | -12,1 -11,2 -8.31% | -9,48 -10,5 9.36% | -1,13 -12,9 91.27% | -9,11 -10,8 15.68% | -16,7 -12,7 -31.48% | -11,8 -13,2 10.11% | -16,6 -11,8 -41.05% | -31,6 -14,0 -125.56% | -14,4 | -15,5 | -16,6 | -19,1 | -19,1 |
|
EPS USD | Released Forecast Spread | -3,50 -2,38 -47.37% | -2,08 -0,68 -208.15% | -1,48 -1,75 15.27% | -0,75 | -0,54 -0,61 11.48% | -0,92 -0,67 -36.63% | -0,48 -0,53 10% | -0,64 -0,47 -36.17% | -1,16 -0,51 -125.98% | -0,34 | -0,36 | -0,38 | -0,46 | -0,46 |
| Announcement Date | 13/05/22 | 11/08/22 | 14/11/22 | 29/03/23 | 11/05/23 | 08/08/23 | 13/11/23 | 18/03/24 | 15/05/24 | - | - | - | - | - |
| 2024-07-15 01:45 | ADDLIFE AB: Q2 2024 Earnings Release |
| 2024-07-21 | MEDPACE HOLDINGS, INC.: Q2 2024 Earnings Release |
| 2024-07-23 | SYNGENE INTERNATIONAL LIMITED: Q1 2025 Earnings Release (Projected) |
| 2024-07-23 | ALKERMES PLC: Q2 2024 Earnings Release (Projected) |
| 2024-07-23 | IQVIA HOLDINGS INC.: Q2 2024 Earnings Release (Projected) |
| 2024-07-23 | ICON PUBLIC LIMITED COMPANY: Q2 2024 Earnings Release (Projected) |
| 2024-07-24 | LONZA GROUP AG: Q2 2024 Earnings Release |
| 2024-07-25 01:00 | BACHEM HOLDING AG: Q2 2024 Earnings Release |
| 2024-07-25 | PHARVARIS N.V.: Q2 2024 Earnings Release (Projected) |
| 2024-07-26 01:00 | BB BIOTECH AG: Q2 2024 Earnings Release |
Past sector events for Plasmatech Biopharmaceuticals Inc
| 2024-06-07 02:57 | POLARIS GROUP: May 2024 Sales and Revenue Release |
| 2024-05-29 16:01 | IMMUNOVANT, INC.: Q4 2024 Earnings Release |
| 2024-05-23 07:00 | CUREVAC N.V.: Q1 2024 Earnings Release |
| 2024-05-22 01:00 | EVOTEC SE: Q1 2024 Earnings Release |
| 2024-05-21 17:14 | ALVOTECH: Q1 2024 Earnings Release |
| 2024-05-21 07:00 | EXSCIENTIA PLC: Q1 2024 Earnings Release |
| 2024-05-17 02:00 | BIOARCTIC AB: Q1 2024 Earnings Release |
| 2024-05-15 16:05 | CULLINAN THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 2024-05-15 07:00 | PERSPECTIVE THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 2024-05-14 | GNI GROUP LTD.: Q1 2024 Earnings Release |
- Stock Market
- Equities
- ABEO Stock
- Stock
- Calendar Plasmatech Biopharmaceuticals Inc
